REGISTERED COMPANY NUMBER: 07955451 (England and Walès) REGISTERED CHARI NUMBER.. 1147457 Report of the Trustees and Financial Statements for the Year Ended 31 December 2021 THE HPV AND ANAL CANCER FOUMDATION LIMITED Knox Cropper LLP Chartered Accouniants 65 Leadenhall Slreel London EC3A 2AD
THE HPV AND ANAL CANCER FOUNDATION LIMITED Contents of the Finan¢ial Ststements for the Year Ended 31 December 2021 Page Reference and Adminlstratlye Detail$ Report of the Trustees 2 to 14 Independent Examinerfs Report 15 statement of Financial Activities 16 Balance Sheet Notes to the Financial Statements 18 to 26 Detalled Statement of Flnanclal Actlvltles 27 10 28
THE HPV AND ANAL CANCER FOUNDATION LIMITED Refen¢9 and Administrative Detail$ for the Year Ended 31 December 2021 TRUSTEES C Mmada J Amada T Amada C Levett REGISTERED OFFICE 128 City Road London EC1V 2NX REGISTERED COMPANY NUMBER 07955451 (England and Wale51 REGISTERED CHARITY NUMBER 1147457 INDEPENDENT EXAMINER Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD SOLICITORS Stone King 16 St. John's Lane London EC1M 4BS BANKERS HSBC 455 Strand Lond¢)n WC2R ORH Page 1
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 The irustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2021. The trustees have adopted the provisions of Accounting and Reporbng by Charities= Statement of Recommended Practice applicable lo charities prepanng their aOnts in accordance wth the Financial Reporb"ng Stsndard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191. The HPV and Anal Cancer Foundation Limited is a United Kingdom IUK} subsidiary of The HPV and Anal Cancer Foundation in the United Ststes of America IUSAI (Charity EIN-. 27-32175201, which was established April 2010. AJI work undertaken by Ihe UK Foundation is in collatrM)ration with ts parent. The HPV 8nd Anal Cancer Foundation Limited is a tharitable company limrted by shares, incorpor8led in the UK on thé 20th Fèbruary 2012 and règisterèd as a charity on the 25th May 2012. Thè company was established throLJgh its thdes of Association, which established the objecis and powers of the charitable company. All shares in the company are owned by The HPV and Anal Canr Foundation in the USA. The HPV and Anal Cancer Foundation ard consists of four members. The directors are resFK)nsible for the legal, financial, program and managemer)t oversight of the chartty. The iK)ard held its annual meeting on Dember 18. The daily restx)nsibilits"es and mission of the Foundab"on are executed by the teams in the USA and the UK. In the Lqtter, the Director of UK Operab"ons is responsible for the coordination of day-tQ-day activities. When the Trustees advertise for new Lard members. candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction. new trustees are given 8 full introduction to the work of The HPV and An81 Cancer Foundation in addilKJn to ¢opies of the organization's fin8nci81 documènts, baws, and policiès. Risk Poli¢y The reserves policy is to maintain a minimum that enables the organisation to meet ts rinancial commitments for the year, including grants. contracts. and staff salaries. FINANCIAL REVIEW It is important to note that the parent and subsidiary organizations operate as one entity in achiewng the mission of the organization. The revenue for the tharTty 15 dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundakn"on in 2021 was £204,749 and expenditure wa5 £255,874.. Re5er¥es Policy The reserves policy is to maintain a minimum that enables the organisation lo meet its financial commitments for the year, in¢luding grants. contracts, and staff salaries. Page 2
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES Objectives and aims Publlc Bèneflt The trustees have referred lo the guidance contained in the Charity Commission's general guidance on public benefit when reviewng the chartys aims and objecb.ves and in planning future aclivrties. History The Foundation was first estsblished in the USA in 2010 by the siblings who lost their mother. aged 53. to stsge IV HPV-related anal Cancer. Frustrated by the limited theraIrtlc and Community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus IHPV). HPV causes anal canr and at least five other cancers, amounting lo 5°k of cancers worldwide. These cancers are preventable. In 2012, the organization expanded lo the UK with 2013 as ils Iirsl full 0rational year. Mission The HPV and Anal Cancer Foundation emw)wer5 anal canr patients and accelerates prevents.on and research methods that eliminate anal ¢ancer and the wrus that causes the majority of ¢as&s, HPV. Objectives Highlight the relevance of human papillomawrus {HPVI in (x)ntracbng cancer Advocate for prevention methods that will end anal cancer and HPV-relaled cancers, including gender-neutral vaccination., - Acc8lératé a cure for the S¢/0 of all cancers that are c3usÈd by HPV. wth a focus on anal cancer,. and Provide SLJPPOrt lor survivors, caregivers, scientists and prowders connected to anal cancer. The Need A fundamental objective of the Foundation's work is lo redu Ihe inudence of anal cancer and other HPV-relaled cancers. HPV is a very common skin virus that neady every sexually active person will gel at some point in their lives. HPV affects both men and women and is responsible for 5 /. of the world's cancer burden. HPV causes cancers of the anus. CeiX, head and rwk. penis. vagina. and vulva. Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six drfferent types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire ropulation against rt. The most effective Meth to redu cancers related to HPV is to prevent initial infection of the Virus through immunisation. The FoundatK)r) achieves this important aim through its efforts to advanGe equal asS to HPV protection for both boys and girfs through gender-neutral vaccination against the virus. At the inlroduGtion of the vaccine in most countries. only girfs were able to receive this lrfe-saving intervention while bo5 were generally ex¢luded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protectson lo all children in 2011. Following the Foundats'on's five-year advocacy campavjn in the UK. SchbaSed HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girts across Europe, and beyond. While we work to prevent ftjture cases. it is also fundamental that s¢i&nttfi¢ and mèdi¢al disparitiès are addressed for the population that wll continue to be diagnosed with HPV4elated cancers like anal cancer. Treatmenl options have barely progressed Sin the 1970s and minimal research has been undertaken in new therapies. The medical and saentific communities need better research tools and investment in novel ideas to develop a cure. Page 3
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres prowde only limited informats'on specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment. Strategies to Achieve Our Goals We 8¢hieve our mission in the UK and US through lIabOratIon wpih scientist5. ¢lini¢i8n5, survivors, organisations, and government agencies- education of 5tskeholders and the general publi¢- survivor support., and investment in the medical and scientific community to end HPV and the cancers it causes. Specifical, we lake aciion to destigmatize and raise awareness aboul HPV, HPV-relaled cancers, and anal cancer., increase access lo the HPV vaccine: improve screening prolocols and preventalive care,. empower anal cancer thrNers' and accelerate a cure for anal cancer and other HPV-related illnesses. Page 4
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES KEY ACHIEVEMENTS IN 2021 NOMAN Is an Island The NOMAN is an Island Campaign raises awareness about the HPV-relaled canr epidemic in men and women and educates about the importance of universal HPV vaccination while challenging partirypants to extreme endurance races across the worfd. It is through such extreme feats of athlelirysm that NOMEN honour the struggle and isolation that many CAncer patients feel. NOMAN has been an incredibly successful campaign. sin its inaugural event in 2013 wth the BarIona Ibiza.. Row to End HPV, 141 individuals - and their hundreds of suptx)rters- have embraced the cause and our values. These NOMEN have raised awareness about HPV-cancers on a local, national. and intemational scale a5 well a5 funds to support our progratnmes. The passion of our partiupants never ceases to amaze us, especialty in the context of the COVID-19 pandemic. The NOMAN Campaign implemented Ihe necessary parameters and covid regulab'ons to enable our scheduled endurance and awareness events to take place. 2021 saw the return of the NOMAN is an Island.. Ra to End HPV campaign's flagship Barcelona Ibiza ocean rowng events. NOMAN'S wean rowng race pits teams of amateur r¢)wers against each other in a Ihree-day sprint auoss the Mediterranean. Rowng across an ean 15 like no other sport." it is as muGh about the crews. ability to cope mentally as li is about technique and physical strength. Such is the enthusiasm for the event, that in 2015 we intrcxluced a retum leg from Ibiza to Barcelona. The race has seen great interest amongst adventure seekers looking to benefit a cause. Rowers range from people wth no prior experience to more seasoned rowers Icw)king to attempt an ocean row before commith.ng to a larger challenge such as the Pacrfic or Alantic Oceans. Undoubtedly the pandemic impa¢te(I sign ups forthe 2021 editi.on. The uncertsinty around travel restrictions lrfied around 3 weeks before the races themselves, restricting the races to 2 crews for both legs of the race. Enquiries around partiopation for future edilions remains aligned wrth pre pandemic numbers which indicates a return to pre pandemic levels of participation in 2023. for the 101h anniversary edition. 2021 also saw NOMAN riders lake on Haute Route events at Crans-montana and Venloux. The H¥ule Route is the world's most PstIgiouS wling event for amateur ¢ydists. The races provide unparalleled experiences with 3- or 7-day professional road GyGling events in the most iconic GyGling destinations worldwide. During the 34ay events, riders take on some 300km and 8000m+ of vertical ascent, testing themselves against the most infamous climbs in the wodd, all in the name of raising awareness of HPV-relaled cancers. Additionally, the Ventoux evenl saw a firsl with NOMAN lighting up the dirnbs in our ochre gold 'END HPW sod(s. 3 attendees of the event wore the socks wf(h pride and heard from NOMAN co-founder Tristsn Almada on our mission to eliminate HPV cancers at the pre-stage briefing event. Proving that lack of tK)ais or bikes is no impediment to those passionale about ending cancer, our first cohort of runners took on the i¢oni¢ London Marathon. racing the slreets of the capital. We thank all our athletes for their sacrrfice and energy as NOMEN. We look forward lo 2022 and building upon our HaLrte Route partnership and beginning to take the steps in preparation for the 10th anniversary Row to End HPV. HPV ACTION EUROPE NETWORK In 2018 and 2019, the Foundation was involved in discussions to establish an advocacy campaign in EuropÈ to introduce gender-neutral va¢¢inab"on a¢ross the region and completely eliminate HPV-related diseases. Page 5
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES NOMAN has partnered wlh the European Cancer Organisation IECOI lo achieve this mission. ECO works to reduce the burden of canr and improve ouicomes and the quality of care for cancer patients through multidisciplinary initiatives. As the European not-for-profil federation ol member organisations working in cancer, they convene oncology professionals and patients to agree on wlicy, advocate for positive change, and be the united voice of the European cancer community. Together wilh Ihe ECO, the Foundation Iwks forward lo working with European policy maker5 to end the suffering ¢aused by HPV cancets. The main achievements of the HPV Action Nelwork in 2021 were as follows: Securlng commitment to eliminating HPV cancers In Europe'5 Beatlng CanrRr Plan Just 14 months after the establishment of the European HPV Action Netsyort, we achieved a European Commission Yagship. commitment to gender-neutral HPV vaccination_ As a rèsult, for the first timè, the EU will dedicate resources to eliminate all HPVwcaused cancers. Europe's Beating Cancer Plan is the Eu's n)admap lo act against ¢an¢er, mobilising the ¢olle¢live power of EU members to deliver change to benefit ils citizens. It entails four areas". pventiOn, early detection, diagnosis and treatment, and improving the quality of life of cancer patients and suNivors. The section pertinent to our work is.. 3.7 Savin Lives throu h Canr Prevenb"on.' Preventi arhcer5 caused b infections With dèdieAt8d funds under thè EU4Hèalth programme and other funding instruments, Europe's Bèating Cancer Plan will support Member Stales. efforts to extend routine vaccination against human papillomavinjses ol gids and in order to eliminale cerwcal cancer and other cancers caused by human papillomaviruses. The objective is to vaccinate at leasl 90% of the EU target population of girls and lo signrficantly increase the vaccination of iK)ys by 2030". The atK>ve is outlined as a ag$hi initiative on preventK>n'. Needless to say. this is a massive Vlory for our campaign and is indicative that our advocacy and case for action set out in 'Viral Protection= Achieving the Possible. has momentum. You can read the full reFK)rt here. Call for the establishment of an HPV Vaccine Tracker In European Imrnunisation Week 2021 {26 April - 2 May). the European Cancer Organisation'5 HPV Action NebNork ¢alled for the establishment of an HPV Va¢¢ine Tracker to be hosted by the European Centre for Diseasè Prevention and Control IECDCI. This monitoring system would prowd8 invaluablè information aboLJt EU Member Stales. progress towards meeting the Beating Canr Plan's goal of eliminating the cancers caused by HPV. 10 out of 27 EU countries have gender-neutral nalional HPV vanation programmes, and eight others have made a commitment to inlr¢yJuce HPV vaccination for boys. Uptake of the vaccine in many countries is well below 900/0 second dose Completion rates ranging from 14% in Luxembourg to 24Yo in France to 31 % in Germany. No EU country has a vacanabon rate of 90 /0 or more for the second dose. In addition, uptake rates in boys by comparison to gids are also lower, in Italy the varrination rate of boys is 40°k of that of girfs. It is clear however that the COVID19 pandemic has disrupted vaccination programmes and led to a significant fall in uptake rates. Page 6
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES A HPV VacGine TraGker would help monitor progress ti)ward5 Europe's Beating CanGer Plan goals, indicate slow progress and countries where additional suprK)rt may be required, in addition to helping encourage Member States to adopt best practice. It will be a key indi(2tor to the world how the EU is contributing towards a global effort to eliminate HPV cancers. The optimal pktform for the HPV Vaccine Tracker would be provided by the European Centre for Disease Prevention and Conlrol IECDCI, an EU organisation that works to Improve Europe's defen5 against infecb.ous illnesses and has a strong track recoré of work on HPV-relaled issue5. ECDC'S COVID-19 vacryne traGker provides an ideal lempl8te for such 8 model. Seif•sampling and HPV Screening in Europe To eliminate ¢ervi¢al ¢an¢er, there must be a large rise in the use of HPV testing for ¢trrvi¢al ¢an¢er screening. Providing women and people a ceTViX the chance to self-sample foT HPV, often known as self-sampling is an imFK>rtant component of any national screening program. SeW-sampling is especially useful for those who have Irwble 8ccessing normal s¢reening facilrfies. In a position paper published by the Network, the key rK>ints of re¢(xnmend3b"on were.. Self-sampling should form a central component of national TCal can1 screening programmes. Self-sampling should be utilised to retum screening rates to pre-pandemic levels. HPV seK-sampling should be endorsed by the European Commission's guidelines on cervical cancer. There should also be guidance on efftive delwery. Research should continue into the best meth(Kls of delivering effective self-sampling with high levels of uptake as part of cervical cancer $CenIng programmes. Numerous studies have shown that self-sampling may be as accurate as traditional testing and is well received by consumers. In one case study, it is being provided as an altemalive to a clinician assessment in the Netherlands to posibve response from parb"ciparrts. Thè papèr can bé rèad in full hére. HPVTESTIMONIES The human papillomavirus IHPVI and the cancers it causes can devaslate people's lives. We worked wlh survivors of HPV cancers lo become advocates. empowered lo tell their story. They explained how they were diagnosed with canr and their emotions and experienoes a5 they dealt with that, and then started Irtratrnent. Thèy talk about the impa¢t on theii lives and on those around them. and whether they have b&&n able to get back to a 'nom)al' lrfe. They also talk lo us aty)ut their thoughts on HPV Itse the availabilty of vaccination, and whether they would like to see universal vaccination for men and women. Finalty, they gNe us their message to patients and policyTnakers so that others can leam from their stories. Future plan5 The Nelwork rK)w has 47 memberStakehol¢jer$, shown here". https.'Ilwww.europeancancer.orgAopic-networkS11:hpv-ac0n.htM1. In 2022 and beyond, the HPV Action Network will.. Encourage and SUPPK>rt the EC and EU Member States lo implement Europe's Beating Cancer Plan. Make the case for 8¢tion to add$$ the impact of the p8ndemi¢ on vawnab.on and screening programmes. Page 7
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES Identify wunlries in the region that are falling behind on vawnatK>n and weening and enGourage and support advocacy in countries Whe pro9SS seems rK)ssible. Continue to develop HPV Tesb'monies. Build on the momentum created by the WHO'S global strategy for cervical cancer elimination, Europe's Beating Cancer Plan, and rent research sl¥)wng that vaccination can prevent up to 90°k of cervical Cancer cases. Publish research commissioned into an 'umbrell8 VIeW of interventions used to improve HPV vaccine uptake in children, adolescents and young aduhs Ito be completed Spring 20221, Publish research commissioned into the current state of HPV vaccination and cetvical cancer screening programmes across the European region G8ttlng stakèholdgrs round thè tabl8 Director David Wintefflood presented at several roundtables in 2021 on the opportunity provided by gender neutral vaccination programmes lo end preventable cancer. In October, a study published in the Lancet reported that vaccinating gids against HPV in England had cut rates of cerviGal c8nGer by 87¢A. This is incredibly excibng news. and as the ¢ausal agent of 5% of all ¢an¢ers. we Can expe¢t to see r8tes of all HPV ¢an¢ers redu¢e signtficantly over the ¢oming years with increased va¢¢inab"on. To that effect, we renewed calls in the UK lor a catch-up programme for boys who have missed out on this life-saving intervention followng the expansion of the HPV vaccine programme in 2019. Anal Cancèr Foundation Anal cancer is one of the fastest growng cancers in the Unrted States. and steadity incTeasing in the United Kingdom. We continue to work tirelessty to make lrfe better for families facing anal canr through our programs lo raise awareness, accerate early detection, improve qualtty of lrfe, and advance a cure. This year, we made incredible prog$$ raising awareness about the need to refom how anal ¢Jn¢er thrivers are diagnosed and treated. P¢*r to Peer Support Programme and Thriver Edu¢ation In the UK, about 1,500 people, and in the US. about 8.600 are diagnosed wilh anal cancer annually. Anal cancer incidence is increasing and affects more people across the wodd every year. The scKial stigma that anal cancer carries prevents fair and equitable conversation. awareness, and funding to support research and care for people wth the disease. Support and information is limited for anal nCer thrivers lour word for suThivorsl and many thrivers never meet another anal cancer palient. The Foundation provides educatK)nal fonjms and a peer mentoring program to support thrivers to close this gap. The Peer lo Peer support program is a free setvice provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey. Connections are 8vai18ble for anyone at any Gancer stsge from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer joumey by sharing their own experiences on trealment, stigma and scKial experiences relating to an anal canr diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survwors a Vol and a community. The program also matches caregivers together. At the end of 2021. Ihe HPVACF'S Peer-tcFPeer programme included 705 parb"cipanls. Our online educational events continue to prowde hope and sOurceS for thrivers. Our'Taking Care of You". Managing Side Effe¢ts From Treatment For Anal canrf evenl, featuring expert ¢lini¢ians who treat people living with anal canr as well as a panel of thrivers has been wewed by over 4,600 people by the end of 2021. 'Living and Thriving After Treatment for Anal Cancer. Addressing Long Tem Side Effects., was viewed 10,000 limes by the end of the year. Page 8
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES Anal Cancer Patient Conference On Septemb$r 25th, 2021, the Anal Cancer FourKlation hehy the first rtUal Anal Can¢er Patient Conference. Medical professionals spM)ke about anal cancer causes, treatments, arKI how lo miligate the various side effects of chemoradiation. We also heard from advocates who taught us, through sharing their own stories, how to use our personal experiences to advance the fight against anal cancer. Finally, Ihrivers were able to network both in groups and one-on-one whiGh, for many peop, was the fit51 time they were meeting a fellow thriv$r. We created this event as an opportunity for anal canr palients and caregivers to learn from medical professionals, connect with experts and each other, and lake action to empower theMseeS and this community. Over 440 people regISted for the Confence from 20 countries around the world. Feedback from participants induded th*, Y)is is. wthout doubt. one of the finest virtual ¢onferen¢es I've ever attended, personal and professional and I've attended a lotl ""thank you for this conference. It provided me with a lot of information and more confidence to share my own slory and help others become more aware of this disease," and "superb conference- so informative and deeY louchingl Really. thank you!. Anal Cancer Foundation CFOunder Jvstine Mmada faciltsted the dals events. Experts including Drs. Joel Palefsky. Cathy Eng. Karyn Glyxlman. and Paul Romesser spoke about anal cancer causes. Irealments, emerging therapies, and how to mib.gate the varioLJS side effects of ¢hemoradiation. Thrivers were given the opportunity to ask questions live, as well as to connect wth one another. Anal Cancer Thriver and Activist Marcia Cross and Cervivoffs Tamika Felder shared their own stories, guiding the audience in how to use their personal experiences to advan the fight against anal cancer. We would like to make sure every family facing anal canr has access to the same information as their doctors. Recordings of the da5 events are now available on YouTube. We will hold another Anal Cancer Patient Summit in 2022. NCCN treatment guideline5 In 2021, we were thrilled to Partner wrth NCCN to ¢xeate the first anal cancer treatment guide for patients, enabling patients and their caregivers to take charge of their own care and recove. The National Comprehensive Canr Nelwork is an alliance of 31 canr nterS in the USA, recognized for dealing wth complex andlor rare cancers. NCCN Clinical Guidelines are the recognized standard for clinical direction and poli in cancer care and are among the most thorough and frequentty updated clinical practice guidelines avaiL4ble in any area of medicine. Thè intent of the NCCN Guidelines is to assist in tha decision-making process of individuals involved in cancer care-including physicians, nurses, pharmacists, payers, patienis, and their families-with the llmate goal of improving patient ¢are and out¢omes. The creation of a companion guide for patients is the next step forward in empowering patients with accessib information. This new anal cancer treatrnenl guide presents clinical information in an easy-to-read format for people wth ¢ancer and those who support thèm_ The patient guideline is intended to". Equip patients and providers wlh the same infomiation as that of their medical team Ensure that patients, no matter where they are trealed. know vthat the experts agree upon as the standard of treatment and care Empower patients wlh knowledge aL¥)ut all of their treatment and care choices - Allow p8b.ents lo self-advo¢8te for their own t caie Page 9
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES ANCHOR Study A ground-breaking randomised controlled nab.onal tn.al of 4.5+ people has shown that anal cancer can be preventèd by routine screening and Moval of pietancerous cells. The ANCHOR Study hoped to improve patient outcomes for people with anal precancer and rancer by finding the best way to stop anal precancer from progressing to cancer. The Anal Cancer Foundation buiA and led the coalition of organizations that supported and pushed for the study. ANCHOR stsnds for Anal Cancer HSIL Outcomes Research and the study investigated treating anal cancer precursor lesions lo see if this reduGed the canr risk for people liwng wth HIV. ConGeived and led by Anal C3nGer Foundation Soienttfic Advisory Board Member Dr. Joel Palefsky, ANCHOR aimed to reGruit 5,000 people living wth HIV and was randomized into gr(KJps." treatrnent of anal precancer and a control group. The incidence of anal cancer is highest in people living wlh HIV. What was ANCHOR researching. pventIon and e8dy dete¢tion a essenti81 to ending anal ¢an¢er. Yet. desrlle its growing in¢iden¢e and mortality, there are no nab.onal screening guidelines for anal ¢Jn¢er or pcarnr. The rates of cervi¢81 cancer reduced by 800/0 once doctors slarting scteening for and treating cetvical precancer. The hope was that the ANCHOR study would illustrate that treating anal precancer will reduce the risk of anal cancer. The Anchor study had two main objectives.. to determine the effectiveness of screening for and Ireats'ng anal precancer to reduce the incidenoe of anal cancer in HIV-posib"ve men and women. and lo create a bank of blood. anal swab, and tissue specimens to support ¢riti¢al s¢ienttfi¢ studies on how anal ¢ancer progresses. There were two amis in the stLJdy. one ami that r1Ved treatment for anal precancer and a ¢ontrol arm that did not. Ninety percent of anal cancer is caused by the human papillomavirus (HPVI, which can cause changes to the skin around 8nd inside the anus. These changes are called "high*rade squamous intr8epilheli81 lesions" or HSIL. Not all anal HSIL wll develop into cancer. Most HSIL wll go away on their own, bul some bècomè Cancer over time and can eventually sprèad to other parts of thè body. What were the outcomes? For now, we know that NIH halted the study in fall 2021 due to the therapys success in reducing the incidence of anal Canr. Researchers wll compile the data and submit for publication after peer rewew. 11 is expected that the dats will provide guidance on rewmmendations to make anal Gancer prevention programs the stsndard of care for people al high risk of anal cancer. What does this mean for the anal cancer communi Anal cancer is currently rapidty increasing at 3% a sear. More peOe are being diagnosed Tmth late stage anal cancer than ever before. We need standard methods to find it eady. The study proved that treating anal preCanr in people limng with HIV, the group at most high-risk for developing anal (ancer, reduces their cAnr risk. The next step is ensuring this becomes the standard of care so that we can end anal cancer by finding r( and treating r( before it ever becomes cancer. Taking Care of You: Tips and Exercises to Restore Your Pelvic Health After Anal Cancer Chemoradiation Page 10
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES On Anal CanGer Awareness Day, Sunday Marth 21st 2021. Anal CanGer Foundation cTrfounder Justine Almada and tK>ard-certified physical therapist Dr. Allison Romero, PT, DPT of Reclaim Pelvic Therapy hosted a webinar to discuss Taking ca of You." Tips and Exercises to Restore Your Pelvic Health after Anal Cancer Chemoradiation. This hour-long webinar included an overview of the impacts of anal canr treatment as well as a plan to Care for the nerves, MUSC5. and fascia that are affected by themoradiab"on. It ended wrth an audience-led Q&A. The resources we discussed and Ihe physical therapy exeruses Dr. Romero demonstraled and recommended for daity practice can be accessed here. International Anal Neoplasia Society IIANSI IANS, the Inlemational Anal NeopL3sia Medical &xiety. creales medical guidelines and sUPPOrts research essential lo preventing 8nd Ire8ting anal c¥n¢er. IANS created wrth a seeil grant from the Foundation. IANS mission is to prowde a forum for individuals wth a broad spectrum of ba¢kground, wewroints and geographic origin, an exchange of ideas and dissemination of kn¢edge iegarding the pathogenesis, diagnosis, treatmenl and prevention of anal neoplasia. In support of this mission IANS: Develops position papers regarding the pathogenesis. diagnosis. treatment and prevention of anal neoplasia. Represents the consensus opinion of IANS regarding the above topics to other professK)nal societies, public organizations, regulatory aUthor'eS and govemmental bcxjies. Encourages the development of a robust research agenda on the pathogenesis. diagnosis, treatment and prevention of anal neoplasia. Develops educational materials and conduct training courses that enUrage the enty of a broad spectru of clinicians into the field of anal neoplasia. and that furthers the devdopmènt and depth of skills of clinicians needed to optimally diagnose, treat and prevenl anal neoplasia. Develop educational materials for patients with anal neoplasia. We look forward to being part of the next IANS conference whith in 2022 will be held in New Yorf¢ City. Infomiation and Connection The Foundation's anal cancer program website features a wealth of resour and is a source of information. support. and inspiration lor patients and families affected by anal Canr. Our focus is ensuring patients get the infomiation and stjpport they need during their anal cancer joumey. Our Living wth Anal Cancer se¢ts'on features infomation for patients at all stsges of the anal ¢ancer journey from newly diagnosed to tK>st-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensNe source of information on side effects and side effect miligalion during and after anal cancer treatrnenl. This digrtal hub is populated with personal thriver stories Ipalienls stories of their experiens}. informali¢Jn aLM)ut helpful medical resources. and professional mediGal b()dies, as well as oonnections to other patiènts and caregivers through our Peer tr) Pser support programme. Our goal in 2021 continues to be ensuring more anal cancer thrivers have access to the infomiab'on they need to face their canr journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, foused on our expert and popular resources. Page 11
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 OBJECTIVES AND ACTMTIES With the pandemic reducing the iner50n resources available to the anal Gancer community, the need for communication with our community was more important than ever. Our communications strategy focLJsed on consistency and 'being useful., wth content covering treatment and research updates, stories from community members, and explainers of our services and how we SUPFrt)rt the anal cancer community. Returning users now rnake up 20.68% of visrtors v5 16.14OA in 2014 Peer lo Peer support sunups are up 28% on 2020 figure5. and 241 % vs 2014 figu$ Going forward. we aim to Continue prowding all the support the anal Canr community needs. LOOKING AHEAD: 2022 As we look ahead, the HPV and Anal Cancer Foundaticm continues to seek the most effective methods to prevent HPV and cure the cancers it causes. The Foundation wll continue to work tirelessty lo eradicate all HPV-related CanrS by fvrthering public policy and scientific debate. elicib.ng further professional and expert support, encouraging the development of gIonal initiives on va¢¢inating boys, and demonstrating why rt is important to prote¢t 811 children against HPV at the ¢0MMended age. The UK began vaccinating boyB against HPV as pupils relumed lo schools in September 2019 and we will continue to work with stakeholders in the HPV-related disease space to ensure that uplake for this cancer-preventing intervent'on among 12-13 year okl boys is as high as px)ssible. The interruption caused by the pandemic will undoubtedly affect vaccination rates in the UK and iYnd. In the wake of a growng vaccine hesitan¢y sentiment, our work is MO important than ever. Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers wthin its remit, we have a mandate lo gain support and empower stakeholders wrthin member stsles lo eliminate HPV cancers. Wrth over 40 /0 of cancers in the region preventable. the extension ol HPV vaccinab.on programmes lo protect boys as well as gids provides a récognisad and éffèctivè mèans to tscklè cancér. Through the NOMAN is an Island Campaign, collaboralions with advocates and legislators, Media attention and athleb'c event participation, a broader audience is understanding the imKKJrtance of protecting all children against HPV. With the NOMAN side of the organisation leading on HPV-related activities, our platform is growing from which lo broadcast our message. In 2022. we wll continue to partner wlh the Haule Route on further cycling events as their European Charity Pather. furthering the reath of our message lo prevent 50/0 of ¢an¢er, and prOdIng the opportunity lo re¢onne¢t wtth the clsts wtthin our community. We will continue to provide anal cancer thrivers wth infom)ation and suppcxt they need on their journey. In addition, our Peer to Peer supFK)rt programme retains tts impx)rtance in supporting and empowering anal cancer survivors and caregivers. Utiliing digital and live plattomis. we will reach a wider proportion of the anal cancer communty, enabling patients to gain answers to the concems they have and lo connect to other anal cancer patient experien5. We are exGrted by the response to our"A5k the Expert. Sessions and look forward to prowding more touchrK>ints for our community with Ihese and the patient conference in 2022. We thank all of our donors and Ik forward to continuing the mission to empower anal canr palients and accelerate prevention and research methods that eliminate anal Carer and the virus that causes the majority of cases, HPV. Public benefit The trustees have referred lo the guidance contained in the Charity C¢)mmission's general guidance on public benefit when reviewing the ¢hanty$ aims and obiecb.ves and in planning future a¢livrties. Page 12
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 FINANCIAL REVIEW Financial position 11 is important to note Ih8t the parent and subsidiary organizth.ons operate as one entity in achiewng the mission of the organizalion. The revenue for the thartty is dependent on don8b.ons from the public. Income for the UK HPV and Anal Can¢er Foundation in 2021 was £204.749 and eXndItUre was £255,874. Re5er¥es policy The reserves policy is to maintain a minimum that enables the aniSatiOn to meet its financial ¢ommitments for the year, in¢luding grants. contracts. and staff salaries. Going ¢on¢em As stated in note 20, the Trustees have considered the effect of the COVID-19 pandemic. The Trustees consider that the pandemic is likety to cause disrupbon lo the Chariws actiwties but are confident that current reserves and future income will be sufficient to ensure that the Charity remains a going concern for a period of at least twelve months from the date of approval of these financial statements as well as for the foreseeable future. STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document. structure and management The charity is controlled by its goveming document. a deed of trust, and o)nslitutes a lirntted company, limited by guarantee. as defined by the Companies Act 2006. The HPV and Anal Can¢er Foundati mited is a United Kingdom IUKI subsidiary of The HPV and Anal Cancer Foundation in the United States of America IUSAI (Charity EIN-. 27-32175201, which was established April 2010. AJI wk undertaken by the UK F(yJndation is in collaboration with its parent. The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20 February 2012 and registered as a charty on the 25 May 2012. The company was estsblished through its Articles of Asso¢iab"on. which estsblished the ot>je¢ts and powers of the charitsble Company. Ml shares in the Company are owned by The HPV and Anal Cancer Foundation in the USA. The HPV and Anal Canr Foundation t4)ard consists of four members. The Trustees are responsible for the legal, financial, program and managemer)t ¢)versighl of the charity. The Lx)ard held its annual meeting on December 18. The daily responsibilities and mission of the Foundats"on are executed by the teams in the USA and the UK. In the Latter, the Director of UK Operab"ons is responsible for the coordinats.on of day-to-day activities. When the Trustees advertise for new board members. CAndidales are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospects've trustees are interviewed prior lo appointment. As part of their induction. new tnjslees are gwen a full intr¢yJuction to the work of The HPV and Anal Cancer Foundab"on in addit to copie5 of the organizab"on'5 financial documents, baw5 and policE5. Risk management The trust88s have 3 duty to identtfy an¢J review the risks to which the ¢harity is exposed and to ensure appropriate controls aré in place to provide reasonable assurante against fraLJd and error.Thè trustees of the FoLJndation hold the responsibility ol safeguarding the charil¥s assets and systems are in place to mitigate those risks which the charity may face. Page 13
THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2021 This report has been prepared in accordance the special provisions of Part 15 of the Companies Act 2006 relating to small companies. 28.09.2022 Approved by ordef of the board of Irustees on ............................................. and signed on ils behaK by. T AJmad0- Truslee Page 14
Indep•nd•nt Examln•rfs Rèport to the Trnst••s of The HPV and Anal Cancer Foundation Lirnited Independent ¢xamln¢r'$ report to the tmstees of The HPV and Anal Canr Foundatlon Llmlt¢d Ilhe Company'l I report to the charity trustees on my examinatn of the a(tounts of the Company for the year ended 31 December 2021. R¢sponsibiliti•s and basi$ of Trport As thé charitls trustees of thè Company land also its directors f the purposes of company lawl you aro responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 {Ihe 2006 Act'l. Having satisfied myself that the accounts of the Company are rt required lo be audited under Part 16 of the 2006 Act and are eligib for independent examinab"on, I report in respect of my examination of your chariws accoun15 as carried out under seGtion 145 of the charib.es knt 2011 1.the 2011 AGf l. In GatTring out my examination I have followed the Directions given by the Charity Commission under section 145151 Ibl of the 2011 Act. Independent examiner's statemènt I have completed my examination. I confimi Ihat no matters have come to my attention in connection wth the examination giving me cause to believe= accounting re¢x>rds were not kept in respect of the Company as requireil by section 386 of the 2006 Act", or the a¢wunts do not a¢¢ord with those records: or the accounts do not comply wth the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.. or the accounts have not been prepared in accordance with Ihe methods and principles of the Statement of Recommended Practice for accounting and retx)rb"ng by charits.es (applicable lo charrties preparing their accounts in a¢¢ordan¢e wth the Finan(ial ReKK>rb"ng Stsndard 8ppli¢able in the UK and Republic of Ireland IFRS 10211. I have no concerns and have come across no olher matters in connection wilh the examinatM)n lo which attention should be drawn in this repK)rt in order to enable a proper understanding of the accounts to be reached. Richard Billinghurst FCA Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD Date.. 3010912022 Page 15
THE HPV AND ANAL CANCER FOUNDATION LIMITED Statement of Financial Activitie$ Ilncorporating an Income and Expenditure Account) for the Year Ended 31 December 2021 2021 Total funds 2020 Total funds Unrestricted furvJ5 Restricted funds Notes INCOME AND ENDOWMENTS FROM Donations and legacies 2.083 2,083 17,061 Other trading activvties Investment income 202.664 202.664 73,105 20 Totsl 204.749 204.749 90,186 EXPENDrruRE ON Raising funds 56.981 56,981 20,478 Charitable activities Care and Support Awareness Raising Research for a Cure 47.743 146,825 4.325 47.743 146,825 4,325 27,417 76,467 4,906 Total 255.874 255.874 129,268 NET INCOMEIIEXPENDrruRE) (51.1251 151,125) 139,0821 RECONCILIATION OF FUMDS Totsl funds brought forward 114.089 13.100 127.189 166,271 TOTAL FUNDS CARRIED FORWARD 62.964 13.100 76.064 127,189 The notes fomi part of these financial statements Page 16
THE HPV AND ANAL CANCER FOUNDATION LIMITED (REGISTERED NUMBER.. 079554511 Balan¢e Sh¢et 31 December 2021 2021 2020 Notes CURRENT ASSETS Debtors Cash al bank 14 327 83,806 218 135,806 84,133 136,024 CREDITORS AmoLJnts falling due within one year 15 18,069} 18,8351 NET CURRENT ASSETS 76.064 127,189 TOTAL ASSETS LESS CURRENT LIABILITIES 76,064 127.189 NET ASSETS 76,064 127,189 FUNDS Unrestricted funds Restricted funds 17 62,964 13,100 114,089 13,100 TOTAL FUNDS 76,064 127,189 The charrt8ble company is enlide¢J to exemption from aLKirt under secb.on 477 of the Companies A¢t 2006 for thè year èndad 31 Decembèr 2021. The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2(Kl6. The trustees acknowledge their responsibilities for lal ensuring that the charitable company keeps accounting recor(Is that COTnply wth Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair wew of the state of affairs of the charitable company as al the end ol each financial year and OF its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise cornply with the requirements of the C¢)tnpanies Act 2006 relab.ng to financial slatements, so far as applicable to the eharitablé company. Ibl These financial statements have been ppared in a¢cor(lan¢e vnth the pro$10n$ applicable to Charitable companies subject to the small companies regime. The financial statements were approved by Ihe Board of Trustees and authorised for issue on 28.09.2022 . and ve signed on its behalf by. T Am>Ja - Trustee The notes fomi part of these financial statements Page 17
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements for the Year Ended 31 December 2021 ACCOUNTING POLICIES Basis of preparing the financial statements The financial slalements of the charitable company. which 15 8 public benefit enttty under FRS 102, have been preparèd in accordancé wth thè Chartbes SORP IFRS 1021 'Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 leffective 1 January 20191., Financial Rep).g Standard 102'The Financial Reporting Standard applicable in the UK and Republic of Ireland. and the Companies Act 20£. The financial statements have been prepared under the historical cost conventK)n. Going Concern The trustees consider that there are rK) material uncertaintie5 aLKxJl the Charty5 ability to continue as a going conc8rn_ Financial reporting standard 102- reduced disclosure exemption5 The ¢haritable Company has tsken advantsge of the folbwng disclosure exemptions in preparing these financial statements, as pemiitted by FRS 102 The Financial RerK>rting Standard applicable in the UK and Republic of Ireland.: the requirements of Section 7 Statement of Cash Fth. Income All income is recognised in the Statement of Financial Activtbes On the charity has entitlement to the funds, it is probable thal the income will be r1ved and the amount can be measured reliably. Expenditure Liabilities are recognised as experKlrture as soon as there is a legal or constructive obligation committing the charrty to that expenditure, rt is probable that a transfer of e¢onomi¢ benefits will bo required in setuement and the amount of the obligation ¢an be measured reliably. Expenditure is accoLJnted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allwated to activities on a basis consistent wth the use of resources. Grants offered subject to conditions vknich have not been met at the year end date are noted as a ommilment but not ared as expendtiure_ Tangible fixed assets Depreciation is provided at the fdlowng annual rates in order to write off each asset over its estimated useful life. Ocean rowing boat and accessories- over 3 years Taxation The charty is exempl from corporation tax on its charitable activitie5. Fund accounting Unrestricted funds can be used in acccydance wrth the charItate objectives at the discretion of the trustees. Restricted funds can only be used for pacular restricted purposes wthin the objects of the charity. Restrictions arise when specffied by the don or when funds are raised for pacular restricted purposes. Page 18 continued...
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- ¢ontinu for the Year Ended 31 December 2021 ACCOUNTING POLICIES- continued Fund accounting Further explanation of the nature an(1 purFK>se of each fund is included in the rteS to the financial ststements. Pension costs and other postetIrement benefrts The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged lo the Statement of Financial Actimbes in the period to which they relate. Judgments and kèy sources of estlmatlon uncertalnty ND judgement lapart from those involving esbmalesl have been made in the process of applwng the above accounting policies that have a significant effect on amounts recognised in the financial statements. OTHER TRADING AcTIVlEs 2021 2020 Fundraising events 202,664 73,105 INVESTMENT INCOME 2021 2020 Deposit accounl interesl 20 RAISING FUNDS Ralsing donatlons and Itgaclas 2021 2020 Staff costs Development expenses Donor software subscription Event Expenses Media Support cosis (Operating) 5.900 118 2.002 46.842 5,611 152 1,174 4,2 3,300 6,015 2.119 56.981 20,478 Page 19 continued...
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- ¢ontinu for the Year Ended 31 December 2021 CHARrrABLE ACTIVITIES COSTS Grant fijnding of activities {see rte 71 Direcl Costs (see note 6) Support costs (see note 81 Totals Care and Support Awareness Raising Research for a Cure 34,986 113.037 2.808 12,757 16.423 1.517 47.743 146,825 4.325 17,365 150,831 17,365 30,697 198,893 DIRECT COSTS OF CHARITABLE ACTIVITIES 2021 2020 Staff costs Development Expenses Marketing Miscellaneous Expense Evenl Expenses Media Inlernel and Website 33,429 5.035 43,064 1.682 46,843 20,778 15,713 6,642 12,939 4,226 13.200 6,545 150.831 60,071 GRANTS PAYABLE 2021 2020 Awareness Raising 17,365 13,235 The totsl grants paid to institutions during the year was as folbws.. 2021 2020 European Cancer Organisalion 17.365 13,235 Page 20 continued...
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- ¢ontinu for the Year Ended 31 December 2021 SUPPORT COSTS Governance costs Finance Olher Totals Raising donations and lega¢ies Care and Support Awareness Raising Research for a Cure 41 71 143 19 1,602 11,859 14,626 1,275 476 B27 1.654 223 2,119 12,757 16.423 1.517 274 29,362 3,180 32,816 Support costs, included in the aLx)ve. are as foJk)ws'. Raising donations nd legacies Carè and Support Awarèness Raising Bank ¢harges Wages Pensions Rent and Rates Insurance Fees and subscriptions Tel8phone. printsng. postage an(1 stationery Sundries Travel and Meètings Stsff Training Consultancy fees Conference expenses Independent Examiner's fee Accountancy and legal fees 41 71 143 732 551 71 1,270 957 12S 357 1.914 250 357 208 135 514 288 270 S68 35 8,114 290 1.6S4 77 38 16 8,115 167 827 71 476 2,119 12,757 16.423 2021 2020 fora Cure Total actimb.es Total activities Bank charges Wages Pensions Rent and Rates Insurance Fees and subscriptions Telephone. printing. postage and stationery Sundries Travél and Meetings 19 274 177 16,082 4.847 8,587 342 258 4.884 3.680 714 413 21 37 soo 404 831 519 1,620 Carried forward 1,211 12,734 31,744 Page 21 continued...
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- ¢ontinu for the Year Ended 31 December 2021 SUPPORT COSTS - continued 2021 2020 Research fora Cure Totsl actiMb"e5 Totsl activ"e$ Brought forward Staff Training Consultancy fees Conference expenses Independent Examinerfs fee A¢countancy and legal fees 1,211 12,734 67 16,229 606 3.180 31,744 5.439 1,196 78 223 480 1,517 32,816 41.499 NET INCOMEI{EXPENDITURE) Net incomellexpenditurel is slated after chargingllcreditingl.. 2021 2020 Independent Examinerfs fee 3.180 3,000 10. TRUSTEES. REMUNERATION AND BENEFs There were no trustees. remunerakn.on or other benefits for the year ended 31 December 2021 nor for the year ended 31 December 2020. Trustees. expenses There were no tnjstees, expenses paid for the year ende(131 Dember 2021 rK)r for the year ended 31 Decèmb8r 2020. 11. STAFF COSTS 2021 2020 Wages and salaries Other pension ¢osts 39.329 4,884 37,406 4,847 44.213 42,253 The average monthty number of employees during Ihe year was as folh)ws.' 2021 2020 Average monthly employees No employees re¢eiveiJ emoluments in ex$ of £60.000. Page 22 continued...
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- ¢ontinu for the Year Ended 31 December 2021 11. STAFF COSTS- continued The key management personnel of the chartty a those persons having authority and SpOnsIbl11ty for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefi15 Paid lo key management personnel in the peri¢xl amounlwj lo £39,329 12020.. £37.4061. 12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTMTIES Unre5triGted funds ReslriGted funds Totsl fvnds INCOME AND ENDOWMENTS FROM Donations and kgacies 17,061 17,061 Other trading activf(ies Investment income 73.105 20 73,105 20 Total .186 90,186 EXPENDITURE ON Raising funds 20.478 20,478 Charitable activities Care and Support Awareness Raising Research for a Cure 27,417 76,467 27,417 76,467 4,906 Total 129.268 129,268 NET INCOMEIIEXPENDITURE) (39,0821 139,0821 RECONCILIATION OF FUNDS Totsl funds brought forward 153,171 13,1(Y) 166,271 TOTAL FUNDS CARRIED FORWARD 114.089 13,1(X) 127,189 Page 23 continued...
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- ¢ontinu for the Year Ended 31 December 2021 13. TANGIBLE FIXED ASSETS Plant and machinery COST Al 1 January 2021 and 31 December 2021 47,250 DEPRECIATION At 1 January 2021 arKI 31 December 2021 47.250 NET BOOK VALUE Al 31 December 2021 At 31 December 2020 14. DEBTORS: AMOUNTS FALLING DUE WH1N ONE YEAR 2021 2020 Gift aid recoverable Prepayments 327 218 327 218 15. CREDITORS: AMOUNTS FALUNG DUE WThHIN ONE YEAR 2021 2020 ial securty and other tsxes Accrued expenses 4,889 3.180 5,835 3,000 8,069 8,835 16. ANALYSIS OF NET ASSETS BEtWEEN FUNDS 2021 Total funds 2020 Total funds Unrestricted funds Restricted funds Current assets Current liabilities 71.033 {8.0691 13.100 84,133 (8.0691 136,024 18,8351 62.964 13.100 76.064 127,189 Page 24 continued...
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- ¢ontinu for the Year Ended 31 December 2021 17. MOVEMENT IN FUNDS Nel movement in funds At 31.12.21 At 1.1.21 Unrestrictèd funds General fund 114.089 151,1251 62,964 Restricted funds Research for a Cure 13,100 13.100 TOTAL FUNDS 127.189 151,125) 76.064 Net movement in funds, included in the above are as folbws= IncomiThJ reSoUS Resources expended Movement in funds Unrestricted funds General fund 204.749 1255,874) {51.1251 TOTAL FUNDS 204,749 125S,874) {51,1251 Comparatives for movement in funds Nel movement in funds At 31.12.20 At 1.1.20 UnrÈstrietÈd fund$ General fund 153.171 139,0821 114,089 Restricted funds Research for a Cure 13.1 13,100 TOTAL FUNDS 166,271 139,0821 127,189 Comparative net movement in funds. included in aly)ve are a5 folk)ws'. Incoming resources ReSoUrS expended Movement in funds Unrestrlctèd funds General fund 90.186 1129,2681 {39,0821 TOTAL FUNDS 90,186 1129,2681 {39,0821 Page 25 continued...
THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- ¢ontinu for the Year Ended 31 December 2021 17. MOVEMENT IN FUNDS - continued Capitsl fund The HPV and Anal Canr Foundab"on Limrted has shareholder capital equal lo £1 and is owned by HPV and Anal Can¢er Foundation. a registèred charity in the Untied States of Ameri¢a, EIN 274217520. Rèsèarch for a Cure Fund The fund was set up to award grants lo research wll advan development of effective treatments for anal and all HPV-related cancers. 18. RELATED PARTY DISCLOSURES There were no related party transactions for the year erKJed 31 December 2021. 19. GOING CONCERN The Trustees have considered the effect of the COVID-19 pandemic in 2020 and into 2021 on the Charitys activities. While the outbreak is likety to cause some changes lo the charws business. the Charity Currently holds a ¢omf(rtable level of reserves and its fixed ¢osts are not signifi¢ant. It has the ability to align its actiwties to the level of reserves avaiLAble. The Trustees are optimistic about the fundraising outlook for the next fvklve months. Page 26
THE HPV AND ANAL CANCER FOUNDATION LIMITED Detailed Statement of Finan¢ial A¢tivitie$ for the Year Ended 31 December 2021 2021 2020 INCOME AND ENDOWMENTS Donatians and l•ga¢i¢$ Donations 2,083 17,061 Other trading activities Fundraising events 202,664 73,105 Inv8stm8nt Incomè Dèposit account interèst 20 T¢)tal in¢oming re$our¢e$ 204,749 .186 EXPENDrruRE Raising donations and legacies Wages Development expenses Donor software sUbsption Event Expenses Media S,900 118 2,002 46,842 5,611 152 1,174 4,226 3,300 54,862 14,463 Char5table actlvitiès Wages Development Expenses Marketing Miscellaneous Expense Event Expenses Media Intemet and Websrf(e Grants to institutions 33,429 5,035 43,064 1,682 46,843 20,778 15,713 6,642 12,939 806 4,226 13,200 6,545 13,235 17,365 168,196 73,306 Support eo$ts (Opèrating) Financ• Bank charges 274 177 Other Wages Pensions Rent and Rates Carried forward 16,082 4,847 8,587 29,516 4,884 3,680 8,564 This page d$ not fom) part of the statut¢xy ffinancial statements Page 27
THE HPV AND ANAL CANCER FOUNDATION LIMITED Detailed Statement of Finan¢ial A¢tivitie$ for the Year Ended 31 December 2021 2021 2020 Other Brought forward Insurance Fees and subscriptions Telephone, printing, postage and stationery Sundries Travel and Meetings Staff Training consU5neY fees Conference expense5 8,564 29.516 244 413 714 S63 519 1,620 67 16,229 606 404 831 159 5,439 1,196 29,362 38.202 Governance costs Independent Examinerfs fee A¢¢ountsn¢y and al fees 3,180 2,640 3,180 3.120 Totsl resources exponded 25S,874 129.268 Net expenditure 151,1251 139,0821 This page d$ not fom) part of the statut¢xy ffinancial statements Page 28